(e/z)-sb-1317

(E Z)-Zotiraciclib ((E Z)-TG02) 是一种 CDK2、JAK2和FLT3的抑制剂，IC50分别为 13、73 和 56 nM。

(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride 是有效的 CDK2，JAK2和 FLT3抑制剂。(E/Z)-Zotiraciclib 可用于癌症研究。

Zotiraciclib, also known as TG02 and SB1317, is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property.

(E/Z)-Zotiraciclib ((E/Z)-TG02) citrate 是CDK2、JAK2 和 FLT3 的有效抑制剂，能够用于研究癌症。